Holen Sie sich die Stockscreener-App
131.74
0.19%
0.25
Vorhandelsmarkt:
132.70
0.96
+0.73%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Companies Reporting Earnings Before Tomorrow's Open: GE, Abbott, PepsiCo, and More - AInvest
Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Here's what to expect from Abbott's Q2 earnings - MSN
Here's what to expect from Abbott's Q2 earnings (ABT:NYSE) - Seeking Alpha
A Preview Of Abbott Laboratories's Earnings - Nasdaq
Saudi Arabia In-Vitro Diagnostics Market Report 2025-2030 Featuring Abbott, BD, Bio-Rad Laboratories, Biomerieux, Danaher, Nihon Kohden, Roche, Siemens Healthineers, Sysmex, Thermo Fischer Scientific - Yahoo Finance
Should You Buy or Sell Abbott Laboratories Stock Ahead of Its Upcoming Earnings? - Nasdaq
Jim Cramer on Abbott: “Patience is a Virtue With ABT” - Insider Monkey
Abbott Laboratories (ABT) Q2 Earnings: What To Expect - Yahoo
Abbott Brass Ignoring Call For Formula Plant Probe, Suit Says - Law360
Oppenheimer Reiterates ‘Outperform’ Rating on Abbott Laboratories (ABT) - MSN
Abbott Labs stock price target raised to $147 from $145 at RBC Capital - Investing.com Nigeria
Abbott Labs stock rating reiterated by Piper Sandler ahead of Q2 earnings - Investing.com Canada
BTIG Adjusts Abbott Laboratories Price Target to $148 From $145, Maintains Buy Rating - MarketScreener
RBC Capital Adjusts Abbott Laboratories Price Target to $147 From $145 - MarketScreener
What to Expect From Abbott Laboratories' Q2 2025 Earnings Report - MSN
Countdown to Abbott (ABT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS - Nasdaq
ABT to Report Q2 Earnings: CGM and Cardiac Devices in Focus - TradingView
BTIG Ups Abbott (ABT) Price Target Amid Mixed MedTech Outlook | - GuruFocus
Prostate Care Market Report 2025-2031 | Medtronic, Johnson & Johnson, Boston Scientific, and Abbott Laboratories Dominate through Product Innovations, Clinical Trials, M&As, and Strategic Partnerships - Yahoo Finance
3 Profitable Stocks to Research Further - FinancialContent
Here's Why We Think Abbott Laboratories (NYSE:ABT) Is Well Worth Watching - Yahoo
Evercore ISI Group Boosts Abbott Laboratories Price Target to $145.00 - AInvest
Abbott Laboratories: Buy Rating Supported by Strong Operational Momentum and Favorable Market Conditions. - AInvest
3 Dividend Growth Stocks to Buy and Hold - MSN
Dividend Information and Latest News on Abbott Laboratories Ahead of Its Ex-Dividend Date on Jul 15, 2025 - AInvest
Abbott Labs stock price target reiterated at $145 by TD Cowen on strong outlook - Investing.com South Africa
Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Abbott Laboratories Shows Improved Relative Price Performance; Still Shy Of Benchmark - Investor's Business Daily
Abbott Laboratories Positioned for Growth: Buy Rating Supported by Strong Operational Momentum and Favorable Market Conditions - TipRanks
Is It Time To Buy Abbott Stock Now? - Nasdaq
Citigroup Adjusts Abbott Laboratories Price Target to $157 From $155, Maintains Buy Rating - MarketScreener
Abbott Laboratories (NYSE:ABT) Expands Diabetes Care with FreeStyle Libre 3 Plus Launch in Canada - simplywall.st
Should You Buy Abbott Stock At $135? - Forbes
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Abbott Laboratories Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) - Benzinga
2 Dividend Stocks to Buy for Decades of Passive Income - The Motley Fool
Abbott Laboratories: A Steady Hand in Volatile Markets Through TSR and Dividend Resilience - AInvest
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
Abu Dhabi Pharmaceutical Partnership Could Be A Game Changer For Abbott Laboratories (ABT) - simplywall.st
Abbott Laboratories: FreeStyle Libre CGMs And EPD Business Driving Positive Momentum - Seeking Alpha
Abbott Laboratories: A Contrarian Gem in a Lynch-Driven World - AInvest
Abbott Laboratories: A Resilient Earnings Machine Trading at a Discount - AInvest
Abbott Hosts Conference Call for Second-Quarter Earnings - Yahoo Finance
State awards $500,000 for realignment of Bishop Road and Nims Road for Abbott Labs site in BG - BG Independent News
Life Experiences Shape Our Work - Abbott
OUR PEOPLE AND CULTURE - Abbott
Abbott Defeats Whistleblower Suit Over Diabetic Supplies Bills - Bloomberg Law News
The Zacks Analyst Blog Highlights Meta, Palantir, Abbott Laboratories, SandRidge and CompX - Yahoo Finance
Is Trending Stock Abbott Laboratories (ABT) a Buy Now? - Yahoo Finance
India Medical Nutrition Market Future Trends and Scope Analysis - openPR.com
Abbott, MSD Forge Diabetes‑Drug Pact For Wider Indian Reach - BW Healthcare World
Abbott Labs stock price target maintained at $140 by Oppenheimer - Investing.com India
Leerink Partners Begins Coverage on ABT - Insider Monkey
10 Best Dividend Stocks to Buy for Dependable Dividend Growth - Insider Monkey
Who Rules Homecare Clinical Nutrition Market? Abbott, Danone, - openPR.com
Health Canada approves Abbott’s i-STAT TBI test for suspected concussions - Medical Device Network
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management - Insider Monkey
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q1 Earnings? - FinancialContent
Abbott (ABT) Stock Dips While Market Gains: Key Facts - Nasdaq
Eaton makes a move outside of the data center — plus, what's new with Abbott Labs - CNBC
Abbott Wins Dismissal of Whistleblower’s Medicare Fraud Suit - Bloomberg Law News
0.28%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):